Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co
Ratings for NewAmsterdam Pharma Co (NASDAQ:NAMS) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $45.5, along with a high estimate of $50.00 and a low estimate of $37.00. Observing a 10.98% increase, the current average has risen from the previous average price target of $41.00.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of NewAmsterdam Pharma Co among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Serge Belanger | Needham | Raises | Buy | $48.00 | $46.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $47.00 | $44.00 |
| James Condulis | Stifel | Raises | Buy | $50.00 | $44.00 |
| Asad Haider | Goldman Sachs | Raises | Neutral | $37.00 | $30.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NewAmsterdam Pharma Co. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NewAmsterdam Pharma Co compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of NewAmsterdam Pharma Co's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into NewAmsterdam Pharma Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on NewAmsterdam Pharma Co analyst ratings.
About NewAmsterdam Pharma Co
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Breaking Down NewAmsterdam Pharma Co's Financial Performance
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: NewAmsterdam Pharma Co's revenue growth over 3M faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately -98.8%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: NewAmsterdam Pharma Co's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -20691.09%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): NewAmsterdam Pharma Co's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.56%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): NewAmsterdam Pharma Co's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.99%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
Understanding the Relevance of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.